AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results; Reaffirms Fiscal Year 2024 Guidance
Fiscal Year 2024 First Quarter Highlights Net sales of $78.7 million as reported Includes $0.7 million of Dialysis and BioSentry...
Cancer
Salix Pharmaceuticals Partners with Bellamy Young
Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting...
BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)...
A New Publication Highlights the Use of cResponse in the Assessment of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer
A recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and...
Massive Bio Pioneers Clinical Trial Recruitment Innovation with Strategic Support from Evernorth Health, Inc.
Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven TechnologiesNEW YORK--(BUSINESS WIRE)--Massive Bio Inc., a trailblazing...
Delphinus Medical Technologies Appoints Scott A. White as New CEO
Long-time CEO Mark J. Forchette to retireNOVI, Mich.--(BUSINESS WIRE)--#SoftVue--Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™...
Carebox Welcomes THANC to the Carebox Connect Network
THANC Guide resource center for thyroid, head and neck cancer patients will now feature Carebox Connect for clinical trial search...
BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer
The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or...
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent...
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose...
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed...
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on...
Neural Therapeutics Announces Board of Directors Appointments and IP Development Agreement with Validity Labs
Toronto, Ontario--(Newsfile Corp. - October 3, 2023) - Neural Therapeutics Inc. ("Neural" or the "Company") is pleased to announce the...
Angle PLC Announces Parsortix Outperforms Standard for DTC Harvest
PARSORTIX SYSTEM OUTPERFORMS CURRENT LABORATORY STANDARD FOR DISSEMINATED TUMOUR CELL HARVEST DTCs linked to cancer relapse even after prolonged remissionDTCs...
Mevion and RaySearch: A Synergy of Innovation Transforming Proton Therapy
Mevion and RaySearch re-imagine novel solutions to advance the use of emerging proton therapy technologies and empower medical providers to...
Edward Owusu Kwarteng, Ph.D., BSc, MSc, Honored With The 2023 ASH-CIBMTR-ASTCT Career Development Award
NMDP/Be The Match and the CIBMTR, leaders in Cell Therapy research, provide the award to support future leaders and accelerate...
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early...
Clade Therapeutics Announces the Acquisition of Gadeta B.V.
Expands Clade’s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated...
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Interim results for the six months ended 30 June 2023
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa...